<DOC>
	<DOCNO>NCT02452190</DOCNO>
	<brief_summary>The primary objective study determine effect reslizumab ( 110 mg ) administer subcutaneously every 4 week clinical asthma exacerbation adult adolescent asthma elevate blood eosinophil inadequately control standard-of-care asthma therapy .</brief_summary>
	<brief_title>Study Reslizumab Patients With Uncontrolled Asthma Elevated Blood Eosinophils</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Written inform consent obtain . The patient male female , 12 year age old , diagnosis asthma . The patient FEV1 reversibility accord standard American Thoracic Society ( ATS ) European Respiratory Society ( ERS ) protocol . The patient require inhaled corticosteroid . The patient require additional asthma controller medication besides inhaled corticosteroid . patient history asthma exacerbation . The patient must willing able comply study restriction , perform requisite procedure remain clinic require duration study period , willing return clinic followup evaluation specify protocol . Additional criterion may apply , please contact investigator information The patient clinically significant , uncontrolled medical condition ( treat untreated ) would interfere study schedule procedure , interpretation efficacy result , compromise patient 's safety . The patient another confound underlying lung disorder The patient know hypereosinophilic syndrome . The patient diagnosis malignancy within 5 year screen visit , except treat cured nonmelanoma skin cancer . The patient pregnant lactate woman , intend become pregnant study . Any woman become pregnant study withdrawn study . The patient current smoker smoking history . The patient participate clinical trial within 30 day 5 halflives investigational drug screening , whichever longer . The patient previously expose reslizumab . The patient history immunodeficiency disorder include HIV . The patient current suspect drug alcohol abuse . The patient active helminthic parasitic infection treat one within 6 month screen . The patient history allergic reaction hypersensitivity component study drug . Additional criterion may apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>